4D-710, 4D Molecular Therapeutics’ (4DMT) gene therapy candidate for treating cystic fibrosis, showcased CFTR transgene RNA and protein expression in all 10 participants treated at the higher and lower dose levels with follow-up up to 12 months in the phase 1/2 AEROW clinical trial (NCT05248230).